source
- Attovia Therapeutics raises $289 million in IPO, adding third I&I drug to market debutAttovia Therapeutics, a biotech focused on immunology and inflammation, completed an initial public offering that raised about $289 million. The funds will support the development of three I&I dru…
- Only one third of US prostate cancer patients received pre-biopsy MRI in 2022, far below Western normsMRI is considered the standard pre-biopsy imaging tool for prostate cancer in most western nations, yet a new analysis shows that only about a third of US cases used it in 2022. In the United Stat…